Tristan Shaffer
Overview
Explore the profile of Tristan Shaffer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
1227
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heilig R, Eckenberg R, Petit J, Fonknechten N, Da Silva C, Cattolico L, et al.
Nature
. 2023 Jul;
620(7973):E17.
PMID: 37491470
No abstract available.
2.
Balbach M, Axelrod M, Balko J, Bankhead A, Shaffer T, Lim L, et al.
Transl Lung Cancer Res
. 2023 Mar;
12(2):257-265.
PMID: 36895920
Background: Identifying a circulating biomarker predictive of immune checkpoint inhibitor (ICI) benefit in patients with small cell lung cancer (SCLC) remains an unmet need. Characteristics of peripheral and intratumoral T-cell...
3.
Mondaca S, Lebow E, Namakydoust A, Razavi P, Reis-Filho J, Shen R, et al.
Lung Cancer
. 2021 Oct;
162:210.
PMID: 34625293
No abstract available.
4.
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping
Lawrence M, Tamen R, Martinez P, Sable-Hunt A, Addario T, Barbour P, et al.
JTO Clin Res Rep
. 2021 Sep;
2(4):100151.
PMID: 34590008
Introduction: Remote consent and enrollment offer a unique opportunity to provide rare cancer populations with access to clinical research. The genomic analysis of plasma cell-free DNA (cfDNA) permits remote characterization...
5.
Smith J, Balar A, Lakhani D, Kluwe C, Zhao Z, Kopparapu P, et al.
JTO Clin Res Rep
. 2021 Sep;
2(3):100110.
PMID: 34589992
Introduction: Blood-based next-generation sequencing assays of circulating tumor DNA (ctDNA) have the ability to detect tumor-associated mutations in patients with SCLC. We sought to characterize the relationship between ctDNA mean...
6.
Iams W, Kopparapu P, Yan Y, Muterspaugh A, Zhao Z, Chen H, et al.
JTO Clin Res Rep
. 2021 Sep;
1(2):100024.
PMID: 34589931
Introduction: Most patients (70%) with limited-stage SCLC (LS-SCLC) who are treated with curative-intent therapy suffer disease relapse and cancer-related death. We evaluated circulating tumor DNA (ctDNA) as a predictor of...
7.
Mondaca S, Lebow E, Namakydoust A, Razavi P, Reis-Filho J, Shen R, et al.
Lung Cancer
. 2021 Jul;
159:66-73.
PMID: 34311346
Objectives: Liquid biopsy for plasma circulating tumor DNA (ctDNA) next-generation sequencing (NGS) can detect ALK fusions, though data on clinical utility of this technology in the real world is limited....
8.
Horn L, Whisenant J, Wakelee H, Reckamp K, Qiao H, Leal T, et al.
J Thorac Oncol
. 2019 Aug;
14(11):1901-1911.
PMID: 31446141
Introduction: Despite initial effectiveness of ALK receptor tyrosine kinase inhibitors (TKIs) in patients with ALK+ NSCLC, therapeutic resistance will ultimately develop. Serial tracking of genetic alterations detected in circulating tumor...
9.
Sabari J, Offin M, Stephens D, Ni A, Lee A, Pavlakis N, et al.
J Natl Cancer Inst
. 2018 Nov;
111(6):575-583.
PMID: 30496436
Background: Liquid biopsy for plasma circulating tumor DNA (ctDNA) next-generation sequencing (NGS) is commercially available and increasingly adopted in clinical practice despite a paucity of prospective data to support its...
10.
Wheeler M, Lannert K, Huston H, Fletcher S, Harris S, Teramura G, et al.
Genet Med
. 2018 Jun;
21(2):477-486.
PMID: 29955105
Purpose: Rh antigens can provoke severe alloimmune reactions, particularly in high-risk transfusion contexts, such as sickle cell disease. Rh antigens are encoded by the paralogs, RHD and RHCE, located in...